John Q. Trojanowski American medical researcher
Trojanowski, John Q.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 64257210 (Personal)
Permalink: http://viaf.org/viaf/64257210
Preferred Forms
-
100 0 _
‡a
John Q. Trojanowski
‡c
American medical researcher
-
100 0 _
‡a
John Q. Trojanowski
‡c
American medical researcher
-
200 _ |
‡a
Trojanowski
‡b
John Q.
-
100 1 _ ‡a Trojanowski, John Q.
-
100 1 _ ‡a Trojanowski, John Q.
-
100 1 _
‡a
Trojanowski, John Q.
-
100 1 _
‡a
Trojanowski, John Q.
(sparse)
-
100 1 _ ‡a Trojanowski, John Q.
-
100 1 _ ‡a Trojanowski, John Q.
-
100 1 _
‡a
Trojanowski, John Q.
4xx's: Alternate Name Forms (9)
Works
| Title | Sources |
|---|---|
| Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation |
|
| The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts |
|
| The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice |
|
| A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research |
|
| A morphometric study of the endocytosis of wheat germ agglutinin-horseradish peroxidase conjugates by retinal ganglion cells in the rat |
|
| Neurodegenerative dementias, c2000: |
|
| The neuropathology of dementia / edited by: Margaret M. Esiri, Virginia M. -Y Lee and John Q. Trojanowski. - Cambridge, 2004. |
|
| A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. |
|
| The older rabbit as an animal model: implications for Alzheimer's disease |
|
| A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease |
|
| The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort |
|
| The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease |
|
| The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. |
|
| A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank |
|
| The power of neuroimaging biomarkers for screening frontotemporal dementia |
|
| An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype |
|
| The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases |
|
| A review and rationale for the use of genetically engineered animals in the study of traumatic brain injury |
|
| A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. |
|
| The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). |
|
| The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury |
|
| Rozpoznawanie i leczenie otępienia z ciałami Lewy'ego : czwarte stanowisko DLB Consortium = Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium |
|
| Rubin's pathology : clinicopathologic foundations of medicine |
|
| The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates |
|
| The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration |
|
| The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease |
|
| Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models |
|
| Therapeutic strategies for the treatment of tauopathies: Hopes and challenges |
|
| Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. |
|
| Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex |
|
| TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia |
|
| TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions |
|
| The TMEM106B locus and TDP-43 pathology in older persons without FTLD |
|
| TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways |
|
| Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. |
|
| Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice |
|
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers |
|
| Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers |
|
| Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome |
|
| The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems |
|
| Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin |
|
| Transfectable and transplantable postmitotic human neurons: a potential "platform" for gene therapy of nervous system diseases |
|
| Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid |
|
| Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions |
|
| Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration |
|
| Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease |
|
| The transitional association between β-amyloid pathology and regional brain atrophy |
|
| Transmission of tauopathy strains is independent of their isoform composition |
|
| Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats |
|
| Transplantation of embryonic dopamine neurons for severe Parkinson's disease |
|
| Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain |
|
| Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging |
|
| TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease |
|
| Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury |
|
| Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease |
|
| Typical and atypical pathology in primary progressive aphasia variants |
|
| Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies |
|
| Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies |
|
| UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis |
|
| Unexpected abundance of pathological tau in progressive supranuclear palsy white matter |
|
| The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease |
|
| 'Unfolding' pathways in neurodegenerative disease |
|
| Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice |
|
| Update on the neuropathological diagnosis of frontotemporal dementias |
|
| Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice |
|
| Utility of amyloid PET in the differential diagnosis of dementia: An autopsy-confirmed series |
|
| Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium |
|
| Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects |
|
| Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment |
|
| Variants associated with Gaucher disease in multiple system atrophy |
|
| Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration |
|
| Vascular disease and dementias: paradigm shifts to drive research in new directions |
|
| Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline |
|
| Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. |
|
| Vulnerability of the neuronal cytoskeleton in aging and Alzheimer disease: widespread involvement of all three major filament systems. |
|
| Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). |
|
| White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration |
|
| A yeast functional screen predicts new candidate ALS disease genes |
|
| α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies |
|
| Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration |
|
| α-Synuclein modulates tau spreading in mouse brains |
|
| α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies |
|
| α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous αSyn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons |
|
